Fuminori Yoshida
Founder chez SYMBIO PHARMACEUTICALS LIMITED
Fortune : 1 M $ au 31/03/2024
Profil
Fuminori Yoshida is the founder of three companies.
He founded Nippon Bio-Rad Laboratories in 1980, Amgen KK in 1993, and SymBio Pharmaceuticals Ltd.
in 2005.
At Nippon Bio-Rad Laboratories, he held the title of President from 1980 to 2010.
At Amgen KK, he held the title of President from 1993 to 2010.
At SymBio Pharmaceuticals Ltd., he currently holds the title of President, CEO & Representative Director.
Mr. Yoshida's former jobs include being the President & Chief Executive Officer of Syntex Japan Co., Ltd., and a Principal at both Mitsubishi Corp.
and AHS Japan, Inc. Mr. Yoshida received his undergraduate degree from Gakushuin University in 1971, and his graduate degrees from Massachusetts Institute of Technology in 1973 and Harvard University in 1975.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 1 179 700 ( 2,63% ) | 1 M $ | 31/03/2024 |
Postes actifs de Fuminori Yoshida
| Sociétés | Poste | Début |
|---|---|---|
| SYMBIO PHARMACEUTICALS LIMITED | Founder | 25/03/2005 |
Anciens postes connus de Fuminori Yoshida
| Sociétés | Poste | Fin |
|---|---|---|
| Syntex Japan Co., Ltd. | President | - |
| AHS Japan, Inc. | Corporate Officer/Principal | - |
Amgen KK
 Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The private company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Founder | - |
| MITSUBISHI CORPORATION | Corporate Officer/Principal | - |
| Nippon Bio-Rad Laboratories | Founder | - |
Formation de Fuminori Yoshida
| Harvard University | Graduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| Gakushuin University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MITSUBISHI CORPORATION | Distribution Services |
| SYMBIO PHARMACEUTICALS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Amgen KK
Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The private company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Health Technology |
| Nippon Bio-Rad Laboratories | |
| AHS Japan, Inc. | |
| Syntex Japan Co., Ltd. |
